Drugs / TQJ230
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06267560 | Apr 2024 → Mar 2026 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT04023552 | Dec 2019 → Jun 2026 overdue | — | Novartis Pharmaceuticals | Active not recruiting | Missed primary |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-09-04 | Novartis Pharmaceuticals | Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD) novartis.com ↗ |
| 2026-09-04 | Ionis Pharmaceuticals | Ionis partner Novartis announces Lp(a)HORIZON Phase 3 topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD) ionis.com ↗ |
| 2021-08-02 | Ionis Pharmaceuticals | Lp(a) HORIZON achieves 50% enrollment in trial to assess the safety and efficacy of pelacarsen in reducing recurrent cardiovascular events ionis.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TQJ230 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04023552 ↗ |
| Known as | Pelacarsen | “With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD” NCT04023552 ↗ |
| Route | Subcutaneous | “TQJ230 80 mg injected monthly administered subcutaneously” NCT04023552 ↗ |